A 2026 biopharmaceutical review in a journal I do not trust said there is no identified high-affinity receptor, no validated molecular target, and a wide disconnect between the tidy preclinical effects and any coherent pharmacology
Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, et al
Oral administration results in lower systemic availability due to digestive enzymes, though the peptides stability allows local gastrointestinal effects at high concentrations which is why oral delivery is often preferred for BPC-157s gut healing applications
Skin adaptation to copper peptides involves cellular-level adjustments that take weeks to complete
Srensen J, Bengtsson A, Bckman E, Henriksson KG, Bengtsson M.Pain analysis in patients with fibromyalgia
UV light degrades benzyl alcohol